Phase 3 Clinical Trials With Primary Completion Dates in February 2024

This is a list of Phase 3 trials with primary completion dates in February 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ALVO Alvotech 2024-02-01 Phase 3 NCT05986786 Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease
ALVO Alvotech 2024-02-01 Phase 3 NCT05842213 Comparative, Multicenter Study in Subjects With Rheumatoid Arthritis, ALVOFLEX
CASBF CanSino Biologics Inc. 2024-02-01 Phase 3 NCT05951725 A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)
CRNX Crinetics Pharmaceuticals, Inc. 2024-02-01 Phase 3 NCT05192382 A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
EIGR Eiger BioPharmaceuticals, Inc. 2024-02-01 Phase 3 NCT04727424 Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
ITCI Intra-Cellular Therapies, Inc. 2024-02-01 Phase 3 NCT04985942 Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
MNKD MannKind Corporation 2024-02-01 Phase 3 NCT04974528 Afrezza® INHALE-1 Study in Pediatrics
PTGX Protagonist Therapeutics, Inc. 2024-02-01 Phase 3 NCT05210790 A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
RARE Ultragenyx Pharmaceutical Inc. 2024-02-01 Phase 3 NCT05139316 A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)